Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

CIR provides up to 30% in non-dilutive R&D tax relief to eligible research-based French companiesCIR offers significant source of support for on-going MS1819 Phase 2 clinical studies in Europe ...
February 18, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

Presentation to focus on Phase II Trial of MS1819 in Cystic Fibrosis (CF)Discussion of safety and efficacy endpoints of bridging dose safety study NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AzurRx...
January 13, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
January 09, 2020 19:22 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD, in combination with...
January 06, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

BROOKLYN, N.Y., Jan. 06, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
January 03, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for...
November 14, 2019 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for...
October 22, 2019 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma CEO Issues Letter to Shareholders

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies...
October 17, 2019 12:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

Supports Company plan to proceed to higher 4-gram dose of MS1819-SD in next Phase 2 clinical trialNo safety concerns cited for MS1819-SD NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AzurRx...
October 15, 2019 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement...